Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the AI Governance topic
No spam. Unsubscribe anytime.
Members flag AI governance and malnutrition with GLP‑1 drugs as timely, high‑impact topics
Summary
Members and public commenters told the Collaborative that AI governance in healthcare and malnutrition risks tied to GLP‑1 weight‑loss drugs need timely guidance; several speakers argued these topics are practical priorities for statewide guidance and monitoring.
Multiple members and public commenters urged the Collaborative to prioritize AI governance and malnutrition/nutritional risk in the next cycle. Radhika Pop (BRI member) said AI governance is unavoidable: "This is something we cannot run from. This is something we need to use. We need to understand how to utilize AI in a safe way that supports not only our staff...but also our patients." Several members agreed the Collaborative is well positioned to recommend vendor contracting standards, monitoring expectations and equity checks.
Clinicians also raised malnutrition and nutritional risk—particularly the potential for sarcopenia among patients using GLP‑1 receptor agonists for weight loss. An anesthesiologist and other commenters urged the Collaborative to develop screening and perioperative management pathways for patients experiencing rapid weight loss or malnutrition to reduce adverse surgical outcomes. Both AI governance and malnutrition ranked high in the straw polls and were included among the top six topics to be developed further.
The Collaborative asked staff to include AI governance and malnutrition as prioritized development tracks and to recruit appropriate technical and clinical experts for work groups.
